Brean Capital Maintains Buy On Repros Therapeutics Following Management Meetings
In a research report issued today, Brean Capital analyst Jonathan Aschoff maintained a Buy rating on Repros Therapeutics (NASDAQ:RPRX) with a $41 price target, following some management meetings for Repros in Europe.
Aschoff wrote, “We hosted management meetings and remain optimistic for Androxal’s prospects despite the FDA panel on TRT and the Type C nature of Repros’ November FDA meeting, especially valued down here at 3X YE14 cash. Regarding the Type C meeting status, the FDA communicated both the Type B status and the Type C status after the panel on TRT, so it does not make sense that the panel dictated the switch. It makes far more sense that the FDA realized that Repros’ pre-NDA meeting submission lacked the full long-term safety data and as a result did not contain data from an amount of patients required to meet ICH guidelines for patient exposures of at least 12 months. Upon completing the Androxal safety trial, Repros has >1,500 patients exposed at all, >900 patients exposed for at least 6 months, and >200 patients exposed for at least 12 months, and it will therefore be clear to the FDA that patient exposure guidelines have been met. There is so much data from all of Repros’ late stage clinical trials that makes a compelling case for revisiting exactly how one should treat secondary hypogonadism, and it makes no sense to us why the FDA would either discourage the filing of such a body of information, or issue an RTF upon its first glance. As a result, the stock, in our view, should recover from its current range once the bear case, underpinned by an expectation of no NDA filing, fails to pan out.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jonathan Aschoff has a total average return of 11.8% and a 60.5% success rate. Aschoff has a -36.5% average return when recommending RPRX, and is ranked #193 out of 3343 analysts.